• Cullinan Therapeutics’ third-quarter 2026 net loss narrowed year over year to $49.4 million.
• General and administrative expenses fell 9% to $12.4 million, while research and development spending declined to $40.2 million.
• Cash and investments totaled $313.8 million at September 30, with cash resources expected to fund operations into 2029.
• Taiho initiated zipalertinib’s first-line combination therapy NDA submission, with completion expected in November.
• CLN-978 multi-dose data across three autoimmune indications will be shared in December.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-454408), on November 10, 2026, and is solely responsible for the information contained therein.